NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 52 filers reported holding NEUBASE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $14,129 | -0.1% | 76,372 | +2.7% | 0.00% | – |
Q4 2022 | $14,145 | -51.2% | 74,369 | +1.7% | 0.00% | – |
Q3 2022 | $29,000 | -63.8% | 73,122 | -2.8% | 0.00% | – |
Q2 2022 | $80,000 | -43.3% | 75,199 | -0.3% | 0.00% | – |
Q1 2022 | $141,000 | -35.9% | 75,425 | -3.9% | 0.00% | – |
Q4 2021 | $220,000 | -25.4% | 78,512 | -3.9% | 0.00% | – |
Q3 2021 | $295,000 | -29.1% | 81,716 | -6.0% | 0.00% | – |
Q2 2021 | $416,000 | -93.9% | 86,954 | -90.6% | 0.00% | – |
Q1 2021 | $6,868,000 | +5.7% | 929,400 | +0.0% | 0.00% | – |
Q4 2020 | $6,496,000 | -5.6% | 929,233 | +2.5% | 0.00% | – |
Q3 2020 | $6,879,000 | -16.0% | 906,303 | -2.8% | 0.00% | – |
Q2 2020 | $8,189,000 | +2107.3% | 932,650 | +1691.7% | 0.00% | – |
Q1 2020 | $371,000 | -1.1% | 52,053 | 0.0% | 0.00% | – |
Q4 2019 | $375,000 | +260.6% | 52,053 | +150.8% | 0.00% | – |
Q3 2019 | $104,000 | – | 20,757 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Greenlight Capital | 2,027,027 | $14,169,000 | 0.85% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 103,500 | $723,000 | 0.55% |
Sio Capital Management, LLC | 293,699 | $2,053,000 | 0.42% |
GSA CAPITAL PARTNERS LLP | 121,389 | $849,000 | 0.14% |
Frontier Wealth Management LLC | 145,000 | $1,014,000 | 0.08% |
PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $2,174,000 | 0.06% |
Oak Grove Capital LLC | 19,175 | $134,000 | 0.04% |
PREMIER ASSET MANAGEMENT LLC | 14,977 | $105,000 | 0.02% |
Trexquant Investment LP | 15,479 | $108,000 | 0.01% |
PILLAR PACIFIC CAPITAL MANAGEMENT LLC | 19,800 | $138,000 | 0.01% |